Related Experiment Videos
Lipophilic methotrexate conjugates with antitumor activity.
R Pignatello1, G Spampinato, V Sorrenti
1Department of Pharmaceutical and Biological Chemistry, The School of Pharmacy, University of London, UK. pignatel@mbox.unict.it
Summary
Novel lipophilic methotrexate (MTX) conjugates show promise for overcoming MTX resistance in cancer. Certain MTX-gamma conjugates partially circumvent defective transport systems in resistant cells, offering potential for new drug development.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Cancer Biology
Background:
- Methotrexate (MTX) is a crucial chemotherapy agent.
- Acquired resistance to MTX often involves impaired intracellular transport.
- Developing strategies to overcome MTX resistance is vital for improving cancer treatment outcomes.
Purpose of the Study:
- To synthesize and evaluate novel lipophilic methotrexate (MTX) conjugates.
- To assess the efficacy of these conjugates against MTX-sensitive and MTX-resistant cancer cells.
- To investigate the potential of these conjugates to circumvent MTX resistance mechanisms.
Main Methods:
- Synthesis of lipophilic MTX-lipoamino acid conjugates via amide or ester linkages.
- Evaluation of inhibitory activity against bovine liver dihydrofolate reductase (DHFR).
- In vitro assessment of growth inhibition in MTX-sensitive (CCRF-CEM) and MTX-resistant (CEM/MTX) human lymphoblastoid cells.
Main Results:
- Amide conjugates exhibited varying activities against parent cells.
- CEM/MTX cells showed reduced susceptibility to alpha or alpha,gamma-substituted conjugates.
- MTX-gamma conjugates demonstrated similar sensitivity in both cell lines, partially overcoming impaired transport.
- Ester conjugates were active against parent cells but less so against resistant cells.
- Stability studies indicated conjugates are not degraded to MTX in culture medium.
Conclusions:
- Lipophilic MTX conjugates, particularly MTX-gamma types, show potential for treating MTX-resistant tumors.
- These conjugates can partially bypass defective MTX transport systems.
- Further development of these lipophilic MTX conjugates is warranted for overcoming drug resistance in cancer therapy.